Y-TSP-A01 in pancreatic cancer mouse models.Y-TSP-A01 injection and histological analysis of tumors was conducted.Y-TSP-A01, but the tumor size was not reduced.Y-TSP-A01 is a promising RIT agent for pancreatic cancer, although further investigation is necessary to improve the efficacy for the radioresistant types like BxPC-3
INTRODUCTION: \nPancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore,...
Pancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore, additional effe...
International audienceTargeting transferrin receptor 1 (TfR1) with monoclonal antibodies is a promis...
Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of m...
<div><p>Objective</p><p>Pancreatic cancer is an aggressive tumor and the prognosis remains poor. The...
Pancreatic cancer is aggressive and its prognosis remains poor; thus, effective therapy is urgently ...
Objective Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, de-vel...
We radiolabeled the antibody with 125I by the chloramine-T method, and with 67Ga or 89Zr using defer...
Transferrin receptor (TfR) is an attractive molecule for targeted therapy of cancer. Various TfR-tar...
<p>Growth curves of BxPC-3 <b>(A)</b> and MIAPaCa-2 <b>(B)</b> tumors in mice treated with 0 MBq (bl...
The human transferrin receptor (CD71) is a ubiquitously expressed internalising glycoprotein involve...
The goal of this study was to determine whether MUC1 antibody conjugated with a fluorophore could be...
The use of radiolabeled antibodies that are able to target primary tumors as well as metastatic tumo...
The goal of this study was to determine whether MUC1 antibody conjugated with a fluorophore could be...
The contribution of integrin α6β4 (α6β4) overexpression to the pancreaticcancer invasion and metasta...
INTRODUCTION: \nPancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore,...
Pancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore, additional effe...
International audienceTargeting transferrin receptor 1 (TfR1) with monoclonal antibodies is a promis...
Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of m...
<div><p>Objective</p><p>Pancreatic cancer is an aggressive tumor and the prognosis remains poor. The...
Pancreatic cancer is aggressive and its prognosis remains poor; thus, effective therapy is urgently ...
Objective Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, de-vel...
We radiolabeled the antibody with 125I by the chloramine-T method, and with 67Ga or 89Zr using defer...
Transferrin receptor (TfR) is an attractive molecule for targeted therapy of cancer. Various TfR-tar...
<p>Growth curves of BxPC-3 <b>(A)</b> and MIAPaCa-2 <b>(B)</b> tumors in mice treated with 0 MBq (bl...
The human transferrin receptor (CD71) is a ubiquitously expressed internalising glycoprotein involve...
The goal of this study was to determine whether MUC1 antibody conjugated with a fluorophore could be...
The use of radiolabeled antibodies that are able to target primary tumors as well as metastatic tumo...
The goal of this study was to determine whether MUC1 antibody conjugated with a fluorophore could be...
The contribution of integrin α6β4 (α6β4) overexpression to the pancreaticcancer invasion and metasta...
INTRODUCTION: \nPancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore,...
Pancreatic cancer is an aggressive cancer and its prognosis remains poor. Therefore, additional effe...
International audienceTargeting transferrin receptor 1 (TfR1) with monoclonal antibodies is a promis...